Levoleucovorin
- Generic Name
- Levoleucovorin
- Brand Names
- Fusilev, Khapzory
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 68538-85-2
- Unique Ingredient Identifier
- 990S25980Y
- Background
Levoleucovorin is the enantiomerically active form of Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin). Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown...
- Indication
Levoleucovorin is indicated for use as rescue therapy following high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Levoleucovorin, as the product Fusilev (FDA, dosed at one-half the usual dose of racemic d,l-leucovorin), has an additional indication for use...
- Associated Conditions
- Advanced Colorectal Cancer, Folic acid antagonist overdose, Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- Rescue after high-dose methotrexate therapy in osteosarcoma therapy
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Acrotech Biopharma Inc.
- Registration Number
- NCT01820091
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Acrotech Biopharma Inc.
- Registration Number
- NCT01789723
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT01590719
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 62
- Registration Number
- NCT01481545
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT01383707
- Locations
- 🇮🇹
Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy
🇮🇹Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy
🇮🇹IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A, Napoli, Campania, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.